i-SENS, Inc.

i-SENS is a global biotechnology company headquartered in South Korea and operating in over 110 countries, including the United States and Europe. The company is the market leader in Korea's blood glucose monitoring device market and specializes in blood glucose management systems, continuous glucose monitoring (CGM) systems, in vitro diagnostics (IVD), and veterinary diagnostic solutions. i-SENS manufactures the CareSens line of self-monitoring blood glucose systems, which meets ISO 15197:2013 accuracy standards for hematocrit and interference criteria. The CareSens Air continuous glucose monitoring system is the first domestically produced CGM in Korea with CE certification, providing real-time glucose data and trend analysis for diabetes management. The company's IVD System leverages whole blood-based diagnostic technology for point-of-care testing applications. i-SENS operates with an annual production capacity of 2.1 billion blood glucose test strips, supporting millions of patients globally. The company maintains regulatory compliance with FDA and CE certification standards. Recent partnerships include a transformational collaboration with LifeScan to launch the OneTouch® Continuous Glucose Monitoring System, leveraging i-SENS technology. The company serves healthcare systems, diabetes management clinics, point-of-care diagnostic facilities, and veterinary care providers. i-SENS is committed to advancing diabetes care innovation and expanding access to glucose monitoring solutions worldwide.